Instituto Oncologico Veneto, IRCCS

Padova 35128

0 studies enrolling now · 2 studies all time

What they study most

Breast Cancer, HER2 Positive Breast Cancer, Solid Tumor

Studies at this site

• Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations — Completed
• MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients — Stopped early